already in the market !! They got CE approval, are currently distributing in Europe, UK, US. Go to their website. This product is already being sold by a competitor that is located IN THE SAME ZIP CODE AS ARTH !! SAME EXACT PRODUCT.
that is my point. BP will come only after phase 2/3 double blinded placebo data. Current data is not reliable as its too small population, not double blinded, no placebo.
But they need $ to complete phase 2/3. My guess is they will go with Lincoln to move ahead.
easily see stock over 200 by end of year. I assume Minecraft will go live sometime in the summer
They may have a superior product....better than all the competitors.
BUT...here is the issue
They only have funding to take it through EU trials, and CE approval. They have $ till Oct, so no $ to market it in Europe.
Not sure if they need another trial for US. But they won't be getting US approval by Oct. That will likely take more time.
I am assuming no US company is going to buy them until they get US Approval. That is the problem.
Another problem...even though they have better product, competitors likely will not buy them. They have their own products ! Why kill their own and buy this ? j&j etc are not going to buy them.
So too many issues -
 No funding beyond Oct
 No funding for Europe marketing. Need quite some $ for that
 No buyout till US approval
 Likely competition will not buy them. Only chance is a buyout from company not in this biz today. That reduces the list significantly
 Market cap already $45M with no revenue today
so Phase 2/3 double blinded is going to cost 1/2 a million over 6 months ? WOW someone call up BIIB and other big pharmas doing phase 2 and phase 3 ALZ...they are WASTING multi millions !!!! Why do it with 100s of patients, when 60 is good enough for FDA ????
Question..with the 50 people test in Europe, they will get CE approval. So any further human trials not needed ? Or do they need to do another trial in the US to get US approval ?
The 10-14 million you mentioned I assume is the current trial being done right now ?
they have a LOT of shares outstanding for such a small company ...117million...and still only have funding till Oct ? Where is all the $ gone from selling all those shares.
great numbers last qtr was pull in sales from current qtr. Look it up. They lowered current qtr sales. Read their transcript. Its all there. So the beat wasn't that big.
don;t you think it also has to do with retails crashing everywhere ? FL, M, TGT, ROST, DSW all others ? If retail is slowing, it will affect US sales for skx too. Don't be so ignorant.
wow longs here are going really overboard today !
Rett trial only 30 days, and they get FDA approval ? No control arm needed ? They have funding ?
The funding they have is only taking them through the 2 year extension.
remember he has to do 2 things to make stock move up -
partnership AND positive 12/24 week data. One without the other is of no use.
really ? so he told you this after lunch yesterday ?
my point is...they NEED FUNDING. They have 12M in the bank, and with this they cannot start rett, or phase 2/3 alz. ODD means nothing unless they can get funding.
Why are you talking about going to market with Rett, when they first need to get funding, then start phase 2, run it for 2-3 qtrs, get successful results, go into phase 3, run it for 3-4 quarters, get successful results, apply and get FDA approval, market it and THEN get revenue.
Do you know how long that is ? Longs are celebrating today like ODD means $$$
no one is even giving them funds to start ph 2/3 for ALZ !! Forget about Rett.
they said they have funding till October 2016...so the issue isn't as much the timing of the EU approval (that will come if results are good)....but isn't the issue about getting partnership/funding BEFORE Oct ?
AVXL market cap is 150M ONLY due to hope with ALZ...it is not due to all these preclinical orphan designations. If so, then PRAN should not be worth only $5million..they got orphan for hunington disease too.
It all comes down to what AVXL says about ALZ.
they expect much more efficiencies that will start showing this quarter. Under $30 is a great stock to own.
they made 3.12 in Q1....so I assume this year it will be over 13. Current P/E is about 12. Next year will be even lower P/E. Company growing revenue AND earnings both at 100%.
Is it about 10 P/E for 2016 and even less for 2017 ? For a stock growing close to 100%